Work

Abstract LB266: A multicenter phase 1-2a clinical study of Orotecan® (oral irinotecan HCl, VAL-413) in patients with recurrent pediatric solid tumors

Year: 2025

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2025-lb266

Authors: Jeffrey Bacha, Dennis Brown, James Geller, Javier Oesterheld, Patrick Thompson, Aerang Kim, Meghann McManus, Sarath Kanekal, Markos Leggas, Lorena Lopez, Neil Sankar, Noymi Yam, Lars Wagner

Institutions: Cincinnati Children's Hospital Medical Center, Levine Children's Hospital, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Children's National, Sarah Cannon, St. Jude Children's Research Hospital, Duke University

Language: English

Topic: Cancer therapeutics and mechanisms

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4409821039

Cites:

Cited by: 1

Related to: 10